Effects of Corn and Coconut Oils on Lipoprotein Lipids, Insulin Sensitivity and Inflammation

Completed · Not applicable

Conditions studied: Healthy Men and Women

In brief

The objectives of this trial are to assess the effects of corn oil and coconut oil on low-density lipoprotein cholesterol (LDL-C) concentrations, and other aspects of the fasting lipoprotein lipid profile, as well as insulin sensitivity and an inflammatory marker, in men and women.

Key facts

Study ID

NCT03202654

Run by

Midwest Center for Metabolic and Cardiovascular Research

People needed

24

Starts

2017-06-22

Expected to finish

2017-10-31

Last updated by the study team

2018-05-15

Who can join

Age: 18 and older, up to 79. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• BMI of 18.5-34.9 kg/m2.
• Fasting LDL-C level ≥115 mg/dL and <190 mg/dL, and TG level ≤375 mg/dL.
• Judged to be in general good health on the basis of medical history and screening laboratory tests.

You may not qualify if…

• Atherosclerotic cardiovascular disease including any of the following:
• clinical signs of atherosclerosis including peripheral arterial disease, abdominal aortic aneurysm, carotid artery disease [symptomatic (e.g., myocardial infarction, angina, transient ischemic attack or stroke of carotid origin) or >50% stenosis on angiography or ultrasound] or other forms of clinical atherosclerotic disease (e.g., renal artery disease).
• History or presence of clinically important pulmonary (including uncontrolled asthma), endocrine (including type 1 or 2 diabetes mellitus), chronic inflammatory disease (including irritable bowel disease, lupus, rheumatoid arthritis), hepatic, renal, hematologic, immunologic, dermatologic, neurologic, psychiatric, or biliary disorders.
• Known allergy, sensitivity, or intolerance to any ingredients in the study products.
• Uncontrolled hypertension.
• Recent history of cancer, except for non-melanoma skin cancer.
• Recent change in body weight of ± 4.5 kg.
• Recent use of any medications intended to alter the lipid profile [e.g., statins, bile acid sequestrants, cholesterol absorption inhibitor, fibrates, niacin (drug form), omega-3-ethyl ester drugs, or proprotein convertase subtilisin kexin type 9 inhibitors].
• Recent use of any foods or dietary supplement that might alter lipid metabolism [e.g., omega-3 fatty acid supplements (e.g., flaxseed, fish or algal oils) or fortified foods, sterol/stanol products; dietary supplements (including Metamucil® or viscous fiber-containing supplement); red rice yeast supplements; garlic supplements; soy isoflavone supplements; niacin or its analogues at doses >400 mg/d].
• Recent use of weight-loss drugs or programs or antibiotics.
• Recent daily use of non-steroidal anti-inflammatory drugs (except low-dose aspirin) or unstable use of antihypertensive medication.
• Recent use of medications that influence carbohydrate metabolism (e.g., adrenergic receptor blockers, diuretics, hypoglycemic medications, and/or systemic corticosteroids).
• Pregnant, planning to be pregnant during the study period, lactating, or of childbearing potential and unwilling to commit to the use of a medically approved form of contraception throughout the study period.
• Extreme dietary habits (e.g., vegan or very low carbohydrate diet).
• Current or recent history for drug or alcohol abuse.
• History of a diagnosed eating disorder (e.g., anorexia or bulimia nervosa).
• Exposure to any non-registered drug product.

Where it is running

• MB Clinical Research — Boca Raton, Florida, United States
• Great Lakes Clinical Trials — Chicago, Illinois, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.